Introduction
Lessons learned from large gene-expression profiling and histopathological studies performed in the most common non-Hodgkin lymphomas (NHL) have dramatically improved our understanding of these lymphomas. For example, lymphomas that are otherwise indistinguishable by histopathological examination originate from different subsets of normal lymphocytes (i.e. the "cell of origin"), exploit distinct oncogenic pathways and transcriptional programs, and vary in their susceptibility to both conventional and novel therapies. 1 In addition, nonmalignant (i.e. "stromal") cells within the tumor microenvironment promote lymphomagenesis by directly fostering the growth and survival of malignant lymphocytes, suppressing anti-tumor immunity, and driving angiogenesis.
2-4
Subsets of non-malignant lymphocytes may be distinguished by their immunoregulatory and functional properties, including differences in the ability to promote the recruitment, expansion, and functional polarization of both lymphoidand myeloid-derived cells. Many of the functions associated with these disparate lymphocyte subsets are determined by "master" transcriptional regulators that drive lymphocyte differentiation. 5 Therefore, the transcriptional programs that determine lymphocyte ontogeny (and the "cell of origin") likely regulate the tumor microenvironment. While the cell of origin and regulation of the tumor microenvironment are apparently related and interdependent, the association between these two fundamental questions is poorly understood for most NHL, including those that are T-cell derived.
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The heterogeneity of the T-cell lymphomas and poor understanding of their pathogenesis continue to impede their classification and the development of novel therapeutic strategies. 6, 7 In fact, the cell of origin for the most common Tcell lymphoma remains elusive, and is so designated as "peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS)". 7, 8 The association between the cell of origin and the tumor microenvironment is best exemplified by angioimmunoblastic T-cell lymphoma (AITL), an aggressive PTCL that originates from clonally expanded follicular helper T cells (Tfh). 9 Conventional Tfh cells transcriptional repressor Bcl-6. 10 In addition to sharing a common immunophenotype with Tfh cells, AITL and Tfh cells share gene expression profiling similarities. 9 Therefore, the ontogeny of malignant T cells in AITL explains the histologic (e.g. germinal center B-cell and follicular dendritic cell expansion) and clinical (e.g. polyclonal hypergammaglobulinemia, autoimmunity) findings characteristic of this PTCL.
In contrast to AITL, characterized by an expanded meshwork of lymphoma-associated follicular dendritic cells, most T-cell lymphoproliferative disorders are infiltrated by an abundance of myeloid dendritic cells and lymphoma-associated macrophages. 11 These myeloid-derived cells (MDC) within 15, 16 As these cytokines promote alternative macrophage polarization, GATA-3 expression in the T-cell lymphomas was examined, where it was shown in shRNA-mediated knockdown experiments to regulate both IL-10 and Th2-associated cytokine production. Importantly, GATA-3 expression was observed in a subset of PTCL, NOS with distinct molecular and clinicopathological features, including a significantly inferior progression-free and overall survival. 
Methods

Patient Samples and Cell lines
Gene Expression Analysis
For personal use only. Table 3 ) and quantitative RT-PCR (supplementary Table 4 ). Protein expression was determined by western-blot, enzyme-linked immunosorbent assay (ELISA), flow cytometry and immunochemistry.
Alternatively Microphage Polarization
The function of alternative polarized macrophage was examined by mixed lymphocyte reaction with CFSE-dilution assay by flow cytometry. 11 Alternatively polarized microphage in PTCL, NOS specimens and normal tissues were visualized by double immunofluorescence staining of pSTAT3 and CD163 with nuclei stained with DAPI.
Statistical Analysis
Patient clinical data were analyzed using JMP 8 software (SAS, Cary, NC).
Progression free and overall survival were estimated using the Kaplan-Meier method and two-tailed log-rank test. 17 GATA-3 expression was dichotomized and the Cox proportional hazards model used to evaluate its ability to predict OS/PFS and to adjust for the Prognostic Index for PTCL, NOS (PIT). 18, 19 Comparisons among groups were evaluated using a Student t test and all pvalues <0.05 were determined to be statistically significant.
The methods are described more fully in the supplementary methods.
Results
Malignant T cells promote alternative macrophage polarization in an IL-10 dependent manner
For personal use only. 14 Therefore, we examined the activation state of these relevant STATs in monocytes exposed to conditioned media generated from patient-derived T-cell lymphoma (TCL) lines.
STAT3 phosphorylation in response to TCL-conditioned media was observed for many cell lines tested ( Figure 1A ). In contrast, STAT1 phosphorylation was not observed, and STAT6 phosphorylation was noted in monocytes exposed to MyLa-conditioned media only (and was IL-13 dependent, data not shown). IL-10 neutralization in TCL-CM and monocyte cocultures abrogated STAT3 phosphorylation ( Figure 1A ). IL-10 levels were low (or undetectable) in the An alternative approach to therapeutically target macrophage polarization may emerge with improved understanding of the mechanism driving IL-10 and IL-4/ILFor personal use only. on July 15, 2017. by guest www.bloodjournal.org From 13 production in malignant T cells. Therefore, in a separate initiative, we sought to identify factors that regulate cytokine production in these lymphomas.
GATA-3 expression in T-cell lymphomas
Both IL-10 and IL-4/IL-13 play a preeminent role in alternative macrophage polarization and are epigenetically or transcriptionally regulated by the transcription factor GATA-3.
15,16 Therefore, we examined GATA3 expression by immunohistochemistry in T-cell lymphoma specimens ( Figure 3A-B) . GATA-3 expression was observed in 67% of cutaneous T-cell lymphomas (n=43) and in 45% of the most common subtype of peripheral T-cell lymphoma, PTCL, NOS (n=128), but was less prevalent in the other TCL subtypes we examined (Supplementary Table 5 
GATA-3 expression is associated with IL-10 and Th2-associated cytokine production
In order to address the possibility that GATA-3 regulates IL10 and Th2-associated cytokines, GATA-3 was knocked down in the GATA-3 + TCL cells following lentiviral transduction with a GATA-3 targeting or non-specific ("scramble") shRNA. We screened multiple GATA-3 targeting shRNA for the ability to knockdown GATA-3 expression in H9 cells (as these cells highly shRNA (Supplementary Figure 5) . As potential differences in cell proliferation during the in vitro culture could confound this analysis (although such a difference was not observed), IL-10 production was also examined by intracellular cytokine staining, whereby GATA-3 knockdown was similarly associated with diminished IL-10 production (Supplementary Figure 7) . However, an association between GATA-3 expression and the prevalence or density of lymphoma-associated macrophages, including those that were pSTAT3 + /CD163 + , was not observed in the PTCL, NOS cases examined (data not shown).
In addition to its role in epigenetically regulating the IL-10 locus, GATA-3 is also the "master" transcriptional regulator of Th2 differentiation. Multiple lines of evidence suggest that a subset of T-cell lymphomas may represent the clonal expansion of Th2 cells. First, patients with both cutaneous and peripheral T-cell
may present with a concurrent peripheral blood hypereosinophilia.
As Th2-associated cytokines (e.g. IL-5) are required for eosinophil expansion, hypereosinophilia is a harbinger of Th2-biased immunity. Conversely, lymphocytic variant hypereosinophilic syndrome is associated with the clonal expansion of Th2 cells that is not clinically apparent initially, but may eventually evolve into a T-cell lymphoma. 22, 23 Finally, the association of GATA-3 transcripts and GATA-3-dependent cytokines in CTCL has led to the long-held belief that a subset of cutaneous T-cell lymphomas is Th2-derived. 24 Therefore, we next examined the relationship between GATA-3 expression and the Th2-associated cytokines IL-4, IL-13, and IL-5. In cells that were rendered GATA-3 deficient by shRNA-mediated knockdown, the transcription and protein production ( Figure   4C -E) of these Th2-associated cytokines was significantly reduced. As IL-5 is required for eosinophil expansion, we examined the relationship between GATA-3 expression in a cohort of PTCL, NOS patients and the absolute eosinophil count (AEC) at diagnosis. While most GATA-3 + PTCL, NOS were associated with a normal eosinophil count, a direct correlation between GATA-3 expression and the development of hypereosinophilia was observed ( Figure 4F ). Collectively, this data demonstrates that GATA-3 regulates both IL-10 and Th2-associated cytokine production by malignant T cells and may suggest that its expression identifies a distinct subset of T-cell lymphoproliferative disorders. Therefore, we analyzed the expression of IL-10 and both Th1 (interferon-γ, T-bet, CXCR3)-and Th2 (IL-4, IL-5, IL-13, CCR4, GATA-3)-associated transcripts by unsupervised hierarchical clustering in CTCL (n=11 ) and PTCL, NOS specimens (n=31) Figure 4G ). Among PTCL, NOS cases, two dominant subsets were identified.
GATA-3 and Th2-associated transcripts were abundant in a subset that more closely resembled the CTCL cases we examined, and could be distinguished from a subset that was enriched for T-bet, Th1-associated transcripts, and IL-10.
In order to determine whether GATA-3 expression is associated with any distinguishing clinical characteristics, we analyzed GATA-3 expression by immunohistochemistry in a cohort of PTCL, NOS patients.
GATA-3 expression identifies a high-risk subset of PTCL-NOS
GATA-3 expression was dichotomized in a cohort of 66 PTCL, NOS patients (Table 1, Supplementary Table 6 ). In this cohort, GATA-3 expression was associated with significantly inferior progression-free and overall survival ( Figure   5 ). The median progression-free and overall survival observed in GATA-3 + PTCL, NOS was 5 months (4-8 months, 95% CI) and 8 months (5-14 months, 95% CI), respectively. In contrast, the median progression-free and overall survival in GATA-3 -PTCL, NOS was 1.3 years (0.6-1.6, 95% CI) and 1.6 years (0.7-6.9 95% CI), respectively. GATA-3 expression was associated with both advanced age and Ann Arbor stage III/IV disease (Supplementary Table 6 ). Therefore, we analyzed GATA-3 expression as a prognostic factor for survival on both univariate and multivariate analyses, adjusting for pertinent risk factors, including patient age and tumor stage, included in the prognostic index for PTCL, NOS (PIT). 18 On multivariate analysis (Table 2) , GATA-3 expression was associated with inferior progression-free and overall survival when adjusting for high-risk features. In order to determine whether GATA-3 expression identifies a group of Taken together, these data demonstrate that GATA-3-dependent cytokines are exploited to regulate the tumor microenvironment in a subset of high-risk T-cell lymphomas with distinct clinicopathological features.
Discussion
Upon antigenic stimulation naïve CD4 + T cells orchestrate both cellular and humoral immunity by differentiating into Th subsets that are characterized by the production of distinct, and frequently subset-specific, cytokines. Studies performed in murine models using knockout and transgenic technology demonstrate that each Th subset expresses a lineage-specific transcription factor that serves as a "master regulator" of Th cell differentiation. 5 Unfortunately, the cell of origin has remained obscure for most subtypes of PTCL, with the notable exception of AITL 9 and an overlapping follicular variant of PTCL-NOS. 25 However, the results of the present study suggest that analysis of Th-subset specific transcription factors, like GATA-3, may have merit and unveil previously unrecognized subtypes of T-cell lymphomas with similar cytokine-and geneFor personal use only. on July 15, 2017. by guest www.bloodjournal.org From expression profiles and a common cell of origin. Importantly, the finding that GATA-3 expression is associated with distinct clinical and molecular features in a subset of PTCL, NOS has been independently confirmed in a larger cohort of patients included in the International T-cell Lymphoma Project. 26 The epigenetic and transcriptional regulation of most cytokines is complex, and incompletely understood. Therefore, it seems likely that GATA-3 expression, while necessary, may not be sufficient for Th2-associated cytokine production by malignant T cells. Furthermore, stromal elements, including lymphomaassociated macrophages, also shape the cytokine milieu within the tumor microenvironment. Interestingly, IL-10 production was at least partially GATA-3- cells. 33 Similarly, GATA-3 is required for the development of fully functional FoxP3 + regulatory T cells. 34 Therefore, GATA-3 may be co-expressed with additional transcription factors, like T-bet or FoxP3, that were once thought to be For personal use only. on July 15, 2017. by guest www.bloodjournal.org From mutually exclusive. In a preliminary effort to address these possibilities, we examined T-bet and FoxP3 expression in a subset of PTCL, NOS cases and rarely observed GATA-3, T-bet or FoxP3 coexpression (data not shown). 35 Conversely, GATA-3 and Bcl-6 expression may be mutually exclusive, as Bcl-6, a transcriptional repressor expressed by clonally expanded Tfh cells in AITL, represses GATA-3 expression. 36 Therefore, future studies will be needed to define the prevalence and implications of GATA-3 expression in a larger cohort of specific PTCL subtypes. Detection of GATA-3 expression by immunohistochemistry may be insufficiently sensitive or specific to identify T-cell lymphoproliferative disorders with a shared cell of origin or molecular signature, and the optimal cut-off defining positivity will require further study and independent validation. Interrogation of additional GATA-3-dependent gene products (including Th2-associated markers) in future studies may aid in the development of algorithms (akin to those used in diffuse large B-cell lymphoma)
suitable for the identification of these lymphomas.
Disease progression within one year of diagnosis was observed in the vast majority of patients with GATA-3 + PTCL, NOS, most of whom ultimately succumbed to disease, despite therapy with an anthracycline-based regimen (usually CHOP). The rapid rate of disease progression observed suggests that GATA-3 expression may represent a predictive biomarker for primary refractory disease. This could be explained by GATA-3-dependent cell-autonomous effects.
For example, GATA-3 promotes the growth/survival of Th2 cells, 37 and more recently has been implicated in the survival of CD8 + T cells. 38, 39 However, this may be cell context dependent, as GATA-3, despite its role in the development of T-cell progenitors, is not required for their survival. 40 In addition, GATA-3 positive lymphomas may be associated with a unique genetic landscape, as recurrent mutations or chromosomal rearrangements may be restricted to specific T-cell lymphoma subtypes with a shared cell of origin. [41] [42] [43] [44] [45] For personal use only. on July 15, 2017. by guest www.bloodjournal.org From microenvironment. However, it would be naïve to think that their influence is limited to lymphoma-associated macrophages. As STAT3 is critically important in the development of pro-tumoral myeloid-derived cells within the tumor microenvironment, the data we present suggests that the JAK2 inhibitors warrant closer scrutiny as immunomodulatory agents in PTCL.
In conclusion, GATA-3 expression is able to identify a subset of T-cell lymphoproliferative disorders with distinct clinicopathological features, including aggressive disease biology and a dismal prognosis. These findings provide a strong rationale for future and confirmatory studies investigating the role of relevant transcriptional regulators with a well-defined role in T-cell ontogeny, and suggest that a key to understanding the tumor microenvironment in the T-cell lymphoproliferative disorders may be found in their cell of origin.
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